EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Activated Complement System’s Impact in Antiphospholipid Syndrome Thrombosis: From Pathophysiology to Treatment

Sofia Tagara, Serena Valsami iD, Eleni Gavriilaki iD, Elias Kyriakou, Elisavet Grouzi, Paschalis Evangelidis iD, Paraskevi Karvouni, Georgia Kaiafa, Ioannis Papadakis iD, Aristarchos Poulis, Eleni Petrou, Marianna Politou und 1 weitere

Journal of Clinical Medicine · 22.09.2025 · 14 (18) · 6672

DOI: 10.3390/jcm14186672 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Journal of Clinical Medicine, online erschienen am 22.09.2025. Verfasst von Sofia Tagara und 12 weiteren Autor:innen. Beteiligte Einrichtung: Laboratory of Hematology, General Hospital of Chania "St. George", 73100 Chania, Greece. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 106 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Medical School of the National and Kapodistrian University of Athens (NKUA).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Antiphospholipid syndrome (APS) is the most common acquired form of thrombophilia and is associated with the presence of antiphospholipid antibodies (aPL) in the patient’s serum. Until now, the “double-hit” hypothesis remains the prevailing theory for APS pathogenesis. According to this model, the presence of aPL (first hit) is insufficient to trigger thrombosis. A secondary event, such as an inflammatory trigger or vascular injury (second hit), is required to initiate immunothrombosis, which ultimately leads to thromboembolism. Although immunothrombosis has a critical role in several mechanisms, such as in defense against pathogens, chronic immune system activation by aPL appears to disrupt its protective function. In the last three decades, the role of the complement system has gained increasing recognition in the pathophysiology of APS. aPL are involved in the dysregulation of multiple components, such as platelets, β2-glycoprotein I, and complement factor H, resulting in excessive activation of the complement system. Thus, the complement system is a key driver of thrombosis in APS and stands as a promising target for the development of future therapeutic strategies. In the current review article, we aim to summarize the ongoing research regarding the role of complement system dysregulation in APS-associated thrombosis development, while recognizing potential therapeutic targets. In the era of precision medicine, more data concerning targeted therapeutics in the field of APS are essential.

Schlagwörter

Stichwörter der Autor:innen

antiphospholipid syndromecomplementendotheliuminflammationthrombosis

Autor:innen und Institutionen

  • Laboratory of Hematology, General Hospital of Chania "St. George", 73100 Chania, Greece.
  • Hematology Laboratory and Βlood Bank, Aretaieion Hospital, National and Kapodistrian University of Athens, 11528 Athens, Greece.
  • Second Propedeutic Department of Internal Medicine, Aristotle University of Thessaloniki, 54642 Thessaloniki, Greece.
  • Laboratory of Hematology and Blood Bank Unit, "Attikon" University General Hospital, School of Medicine, National and Kapodistrian University of Athens, 12462 Athens, Greece.
  • Department of Transfusion Service and Clinical Hemostasis, "Saint Savvas" Oncology Hospital, 11522 Athens, Greece.
  • School of Medicine, Aristotle University of Thessaloniki, 54634 Thessaloniki, Greece.

ORCID-Profile: Serena Valsami, Eleni Gavriilaki, Paschalis Evangelidis, Ioannis Papadakis

Förderung

  • Medical School of the National and Kapodistrian University of Athens (NKUA)

Zitieren

APA

Tagara, S., Valsami, S., Gavriilaki, E., Kyriakou, E., Grouzi, E., Evangelidis, P., Karvouni, P., Kaiafa, G., Papadakis, I., Poulis, A., Petrou, E., Politou, M., & Kokoris, S. (2025). Activated Complement System’s Impact in Antiphospholipid Syndrome Thrombosis: From Pathophysiology to Treatment. Journal of Clinical Medicine, 14(18), 6672. https://doi.org/10.3390/jcm14186672

Vancouver

Tagara S, Valsami S, Gavriilaki E, Kyriakou E, Grouzi E, Evangelidis P, et al. Activated Complement System’s Impact in Antiphospholipid Syndrome Thrombosis: From Pathophysiology to Treatment. Journal of Clinical Medicine. 2025;14(18):6672. doi:10.3390/jcm14186672

BibTeX
@article{Tagara2025,
  author = {Tagara, Sofia and Valsami, Serena and Gavriilaki, Eleni and Kyriakou, Elias and Grouzi, Elisavet and Evangelidis, Paschalis and Karvouni, Paraskevi and Kaiafa, Georgia and Papadakis, Ioannis and Poulis, Aristarchos and Petrou, Eleni and Politou, Marianna and Kokoris, Styliani},
  title = {Activated Complement System’s Impact in Antiphospholipid Syndrome Thrombosis: From Pathophysiology to Treatment},
  journal = {Journal of Clinical Medicine},
  year = {2025},
  volume = {14},
  number = {18},
  pages = {6672},
  doi = {10.3390/jcm14186672}
}
Kostenlos starten →